RESUMEN
OBJECTIVE:To systematically evaluate therapeutic efficacy of modified Shenqi dihuang decoction in the treatment of chronic glomerular nephritis. METHODS:Retrieved from Wanfang database,CNKI,VIP,CBM,Cochrane Library,Medline, EMBase and PubMed,randomized controlled trials(RCTs)about modified Shenqi dihuang decoction combined with conventional therapy and (or) other Chinese patent medicine (trial group) vs. conventional therapy and (or) other Chinese patent medicine (control group)in the treatment of chronic glomerular nephritis were collected. Meta-analysis was carried out by using Rev Man 5.3 software after literature scanning,data extraction and quality evaluation. Stata 14.0 software was used to conduct Egger test to evaluate publication bias. If publication bias existed,the effect of publication bias on outcome was further evaluated by scissor compensation. TSA v0.9 software was used for trial sequential analysis(TSA)of total efficency. RESULTS:A total of 10 RCTs were included,involving 707 patients. The results of Meta-analysis showed that total response rate of trial group [RR＝1.40,95%CI(1.22, 1.61),P＜0.001] was significantly higher than that of control group; the level of urine protein [SMD＝－1.97,95%CI(－2.92,－1.03),P＜0.001] and Scr [MD＝－28.41,95%CI(－38.95,－17.87),P＜0.001] in trial group were significantly lower than control group,with statistical significance. Publication bias test of total response rate was conducted,and results of it showed that there was publication bias,but bias did not affect the results of this study. TSA analysis showed that the evidence of Meta-analysis was false positive. CONCLUSIONS:Therapeutic efficacy of modified Shenqi dihuang decoction for chronic glomerular nephritis need to be proved by more stringent RCTs.
RESUMEN
Objective To discuss clinical curative effect and value of valsartan combined with Huangkui capsule on the chronic glomerulonephritis proteinuria.Methods 70 cases of patients with chronic glomerulonephritis proteinuria were selected in our hospital,and randomly divided into two groups,35 cases in control group with valsartan oral,80 mg per time,once per day,8 weeks as a course of treatment;35 cases in experimental group, combined with Huangkui capsule on the basis of conventional treatment orally,5 capsules per time,3 times per day,8 weeks for a period of treatment. After 8 weeks treatment,changes of serum creatinine,serum urea nitrogen,the urine protein and clinical therapeutic effect were compared before and after treatment in two groups.Results Contents of serum urea nitrogen,serum creatinine,urine protein were improved in two groups after treatment, and serum creatinine contents of experimental group (153.69 ±13.78)μmol/L was lower than that of control group (179.19 ±23.49)μmol/L,and the difference was statistically significant (P<0.05);serum urea nitrogen contents of experimental group (7.09 ±1.16)mmol/L was lower than that of control group (9.29 ±2.38)mmol/L,and the difference was statistically significant (P<0.05);urine protein contents of experimental group (0.57 ± 0.32)g/L was lower than that of control group (0.89 ±0.26)g/L,and the difference was statistically significant(P<0.05);clinical curative effect of experimental group was better than that of control group,and the difference was statistically significant(P<0.05 ).Conclusion Valsartan combined with Huangkui capsule could effectively reduce albuminuria symptomsin the treatment of patients with chronic glomerulonephritis proteinuria,which has a remarkable effect,and has a positive significance for the renal function recovery.